Gregory S. Blank
Gregory S. Blank is the director of late-stage purification at Genentech, Inc.
Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal Antibodies
Benedicte Lebreton;Amber R. Cothran;Sandy Sargis;Melody Trexler-Schmidt;Binh Q. Thai;Brian Kelley;Gregory S. Blank;Stefanie Sze-Khoo
March 2nd 2009Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: December 9th 2024 | Updated: December 26th 2024
Recap Key Industry Trends for Viral Clearance and NGS
Published: December 7th 2024 | Updated: December 26th 2024
Enhancing Quality Through Training
Published: July 20th 2020 | Updated: December 26th 2024
Contact BioPharm International Editors
Published: July 19th 2020 | Updated: December 26th 2024
Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars
